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Background: Sarcomas are heterogeneous rare malignancies constituting
approximately 1% of all solid cancers in adults and including more than 70
histological and molecular subtypes with different pathological and clinical
development characteristics.
Method: We identified prognostic biomarkers of sarcomas by integrating clinical
information and RNA-seq data from TCGA and GEO databases. In addition, results
obtained from cell cycle, cell migration, and invasion assays were used to assess the
capacity for Tanespimycin to inhibit the proliferation and metastasis of sarcoma.
Results: Sarcoma samples (N = 536) were divided into four pathological
subtypes including DL (dedifferentiated liposarcoma), LMS (leiomyosarcoma), UPS
(undifferentiated pleomorphic sarcomas), and MFS (myxofibrosarcoma). RNA-seq
expression profile data from the TCGA dataset were used to analyze differentially
expressed genes (DEGs) within metastatic and non-metastatic samples of these four
sarcoma pathological subtypes with DEGs defined as metastatic-related signatures
(MRS). Prognostic analysis of MRS identified a group of genes significantly associated
with prognosis in three pathological subtypes: DL, LMS, and UPS. ISG15, NUP50,
PTTG1, SERPINE1, and TSR1 were found to be more likely associated with adverse
prognosis. We also identified Tanespimycin as a drug exerting inhibitory effects on
metastatic LMS subtype and therefore can serve a potential treatment for this type
of sarcoma.
Conclusions: These results provide new insights into the pathogenesis, diagnosis,
treatment, and prognosis of sarcomas and provide new directions for further study
of sarcoma.
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INTRODUCTION
Sarcomas show a substantial degree of heterogeneity attributable
to organ specificity of these cancers. Sarcomas account for
∼1% of all adult and 10% of childhood cancers. They can
develop in any organ or body site including bone, soft tissue,
or skin (1–3). Accordingly, their histopathological characteristics
and clinical phenotypes serve as the core for their diagnostic
criteria (4). Accurate identification and classification are crucial
for successful treatment as responses to specific therapies vary
widely among tumor types of different origin and misdiagnosis
may lead to poor treatment outcomes (5). However, due to
overlap in histopathological features among sarcoma and the
existence of multiple subtypes or variations in a single histology,
pathologists and clinicians increasingly rely on molecular
diagnostic methods (6, 7).
Currently, treatment of sarcoma includes surgical resection,
chemotherapy, and radiotherapy; however, the importance
of employing a comprehensive treatment regimen involving
neoadjuvant chemotherapy and preoperative radiotherapy is
increasing (8–10). Despite these advances, life expectancy of
patients with metastatic sarcoma remains low. According to the
SEER (Surveillance, Epidemiology, and End Results) database
of the National Cancer Institute (NCI), sarcoma survival rates
vary as a function of the extent of spread, with patients
having distant metastases showing a 5-years survival rate of
only 16%, while those with partial lesions or partial metastases
showing 5-years survival rates of >60%. Due to the extreme
degree of heterogeneity within sarcoma, ∼100 recognized
histopathological subtypes with metastasis-related characteristics
have been defined (11).
In this report, we focused on four common sarcoma
pathological subtypes including dedifferentiated liposarcoma
(DL), leiomyosarcoma (LMS), undifferentiated pleomorphic
sarcoma (UPS), and myxofibrosarcoma (MFS). These subtypes
were analyzed using TCGA and GEO gene expression data.
Differentially expressed genes (DEGs) were identified and
grouped in the set of signatures associated with different
sarcoma pathological subtypes; metastatic status [metastasis-
related signatures (MRS)] and potential responsiveness to
treatment were identified. The role of these factors in influencing
sarcoma metastasis can provide important information for
a more thorough understanding and treatment of this type
of cancer.
MATERIALS AND METHODS
Data Acquiring and Preprocessing
Sarcoma-related clinical and RNA-seq data were downloaded
using TCGA GDC API. GSE21050 chip data from Affymetrix
Human Genome U133 Plus 2.0 Array were downloaded from
GEO. TCGA cohort data of sarcoma were preprocessed in the
following steps: (1) remove samples without clinical information
or PFS (progression-free survival) <30 days, (2) remove data
from normal tissue samples, (3) remove genes with 0 FPKM
(Fragments Per Kilobase per Million) in greater than half of the
samples. The GEO data were preprocessed using the following
steps: (1) removal of normal tissue sample data while retaining
only data from tumor tissues, (2) converting themetastasis events
of PFS data from year or month to days, and (3) using the
Bioconductor R package to map the chip probe to the human
gene symbol.
MRS Screening and Functional Annotation
TCGA cohort was grouped according to subtype information
to identify the samples as DL, LMS, UPS, and MFS in the
metastasis and non-metastasis groups. RNA-seq data were then
analyzed using DESeq2. Genes with FDR < 0.05 were defined
as MRS. For the GSE21050 dataset, RMA homogenization was
performed first and then Limma R package was used for analyses
of differences. P < 0.001 was required for the DEGs screening
threshold. The R package clusterProfiler (v3.8) was used for GO
and KEGG functional annotation and enrichment analysis of
identified MRS with the q value (FDR) of <0.05 as the threshold
for significant enrichment.
Prognostic Analysis
The univariate Cox risk regression model was used to analyze
the prognostic relationship between MRS and metastasis events
and log rank p < 0.05 was set as the significance threshold.
The Kaplan–Meier Plotter was used to analyze and display the
prognostic curve of sarcoma subtypes transfer events. The R
package version 3.5.1 was used for the analyses.
TABLE 1 | Clinical sample details.
TCGA GSE21050
Metastasis
No 120 186
Yes 130 100
Metastasis (PFS) * *
No (mean days) 1229.6 1749.51
Yes (mean days) 453.6 853.41
Histological type
DL 57 57
UPS 49 128
LMS 100 75
MFS 24
SS 10
MPNST 8
DT 2
Other 26
Age
<50 51
≥50 199
Gender
Female 136
Male 114
DL, dedifferentiated liposarcoma; UPS, undifferentiated pleomorphic sarcomas; LMS,
leiomyosarcoma; MFS, myxofibrosarcoma; SS, synovial sarcoma; MPNST, malignant
peripheral nerve sheath tumors; DT, desmoid tumors.
* Indicates means with a significant difference.
Frontiers in Oncology | www.frontiersin.org 2 October 2020 | Volume 10 | Article 544956
Li et al. Genes and Drugs to Sarcoma
FIGURE 1 | In TCGA, survival time of patients in the metastasis group was observed to be significantly lower than that of patients with non-metastasis. (A) DL. (B)
LMS. (C) UPS. (D) MFS. In GSE21050, survival time of patients in the metastasis group was also observed to be significantly lower than that of patients with
non-metastasis. (F) LMS. (G) UPS. (E) Only pathological subtypes DL did not observe this significant difference.
Drug Discovery
The L1000FWD (http://amp.pharm.mssm.edu/l1000fwd/)
platform was used to identify small molecules with potential
ability to affect identified DEGs. The L1000FWD database
provides record of the up-regulated/down-regulated genes
induced by treatment of cancer cell lines with more than 16,000
drugs or small molecules. By comparing the identified up-
regulated and down-regulated DEGs to the L1000FWD database
record, it can be inferred which small molecular substances may
have an effect on identified DEGs. The DGIdb database (http://
www.dgidb.org) records more than 40,000 genes and 10,000 drug
interactions and provides records of specific genes and drugs
associated with interactions of these genes. Based on the DEGs
identified, it is possible to identify drugs that have the highest
potential to interact with this gene.
Before using CMap (http://portals.broadinstitute.org/cmap/)
queries, we used bioconductor R package to convert four subtype
MRS gene SYMBOL to Affymetrix probe ID. In the CMap
database, drugs with significant negative scores are predicted
to become new therapeutic drugs for sarcoma. CMap uses the
gene set enrichment analysis algorithm to calculate connectivity
scores, with an average score ≤0.65 used to identify potential
TABLE 2 | MRS statistics.
Dataset Yes/No DL LMS UPS MFS
TCGA Down 89 339 43 224
Up 476 341 182 119
GSE21050 Down* 13 64 38
Up* 32 71 88
Yes indicates transferred and no indicates untransferred. *p <0.001 was established as
the threshold of MRS.
drug candidates. For each probe generated by CMap ≤-0.67 or
>0.67, scores were identified as significant and were used for
pathway analysis as an amplitude of ±0.67 represents a twofold
change between the treatment and the control.
Tissue Samples
Samples of sarcoma and adjacent non-tumor tissues (six of the
10 sarcomas were uterine leiomyosarcomas, three liposarcomas,
and one undifferentiated pleomorphic sarcoma) were collected
from 10 patients (all >16 years of age), immediately placed in
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FIGURE 2 | Screening of MRS in metastasis and non-metastasis sarcoma pathological subtypes. (A) TCGA. (B) GSE21050. Enrichment results of MRS GO Biology
Process in THE TCGA dataset of sarcoma pathological subtypes: (C) DL. (D) LMS. (E) UPS. (F) The enrichment results of MFS MRS KEGG Pathway (MRS of MFS did
not show significant enrichment term on GO, but significant enrichment results were shown on KEGG pathway, so KEGG pathway enrichment results are shown here).
liquid nitrogen and preserved at −80◦C. None of the sarcoma
patients received preoperative anti-tumor therapies. Patients
and their families in this study had been fully informed and
informed consent was obtained from all participants. This
study was approved by the Ethics Committee of Shanghai
Tongren Hospital.
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FIGURE 3 | Relationship between MRS of 3 pathological subtypes of sarcoma and prognosis of metastasis. (A) DL. (B) LMS. (C) UPS (Left panel: TCGA dataset;
right panel: GSE41258 dataset. HR: hazard ratio, p-value is log rank test p). *p < 0.05, **p < 0.001, and ***p < 0.0001.
Cell Lines and Culture Conditions
Sarcoma cells, HT-1080 (National Infrastructure of Cell Line
Resource 3111C0001CCC000070), and SW-982 (National
Infrastructure of Cell Line Resource 3131C0001000700209)
were purchased and authenticated originally by the National
Infrastructure of Cell Line Resource program using short tandem
repeat (STR) analysis; SK-UT-1 cell line was obtained from
ATCC (Manassas, VA, USA). Cells were expanded and frozen
at low passage within 1 month after receipt from the original
stocks. Cells were then thawed and used within 15 passages.
Cells were cultured in medium as suggested by the manufacturer
supplemented with 10% fetal bovine serum, 100 units/ml
penicillin, and 100µg/ml streptomycin at 37◦C in a humidified
5% CO2 incubator.
Cell Proliferation Assay (CCK8 Assay)
For the proliferation assay, sarcoma cells were seeded at 5 × 103
cells/well in 96-well plates and treated with Tanespimycin for
72 h. A 10-µl aliquot of the Cell Counting Kit-8 reagent (Dojindo,
Japan) was added to the cells. Following incubation for 3 h,
absorbance was measured at 450 nm using a spectrophotometer
(Bio-Rad, USA).
RNA Isolation and qRT-PCR Analysis
RNA extraction from tissues was performed using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). RNA was reverse-transcribed
into cDNA with the QuantiTect Reverse Transcription Kit
(QIAGEN, Valencia, CA, USA). Real-time PCR analyses were
quantified by SYBR-Green (Takara, Otsu, Shiga, Japan), and
the levels were normalized to GAPDH levels. Sequences of
upstream and downstream primers were as follows: ISG15,
5′-CGCAGATCACCCAGAAGATCG-3′ and 5′-TTCGTCGCA
TTTGTCCACCA-3′. NUP50: 5′-TCTGGAGGAGGACGCTTT
TCT-3′ and 5′-GGGGCACTGGTTATGTTGTTT-3′. PTTG1: 5′-
ACCCGTGTGGTTGCTAAGG-3′ and 5′-ACGTGGTGTTGA
AACTTGAGAT-3′. SERPINE1: 5′-ACCGCAACGTGGTTTTCT
CA-3′ and 5′-TTGAATCCCATAGCTGCTTGAAT-3′. TSR1: 5′-
CAGCTCCGAAAGCAGAAGAAG-3′ and 5′-GTTCCAGTGT
CCCTATCTTGAAG-3′.
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FIGURE 4 | Expression levels of prognostic MRS in pathological subtypes of sarcomas. TCGA: (A) DL. (C) LMS. (E) UPS. GEO: (B) DL. (D) LMS. (F) UPS. (Left
panel: TCGA dataset. right panel: GSE41258 data set).
Immunohistochemistry
Sarcoma samples were fixed in 10% formalin, embedded in
paraffin, and processed as 5-µm continuous sections. Samples
were dewaxed with ethanol and blocked to inhibit endogenous
peroxidase. They were then heated in a microwave to retrieve
antigens, cooled to room temperature, and then blocked by
incubation in goat serum for 30min at 37◦C. Samples were
incubated in rabbit anti-ISG15, anti-NUP50, anti-PTTG1, anti-
TSR1, and anti-SERPINE1 (Abcam, Cambridge, UK; 1:1,200)
overnight at 4◦C, followed by incubation with horseradish
peroxidase-coupled goat anti-rabbit secondary antibody at 37◦C
for 30min and stained using 3,3′-diaminobenzidine. The cell
nucleus was stained blue by hematoxylin. Sections were then
dehydrated, cleared by xylene, and mounted. ISG15, NUP50,
PTTG1, TSR1, and SERPINE1 expression was detected by
IHC using a streptavidin peroxidase method, with adjacent
tissues as control groups. The experimental procedure was
performed according to the manufacturer’s instructions. The
Image-ProPlus 6.0 Software (MediaCybernetics, USA) was used
to analyze the expression of proteins and statistics on the results
of immunohistochemistry.
Cell Migration and Invasion Assays
Cells were harvested, resuspended in serum-free media, and
placed into the upper chamber of a Transwell membrane
filter (Corning, NY, USA) for migration assays or in the
upper chamber of a Transwell membrane filter coated with
Matrigel (Corning) for invasion assays. Culture medium with
10% FBS and 0/5/10 nM Tanespimycin was added to the lower
compartment of the chamber to serve as a chemoattractant. After
24 h of incubation, cells were stained with methanol and 0.1%
crystal violet, imaged, and counted using anOlympusmicroscope
(Tokyo, Japan).
Establishment of Single-Cell-Derived
Cellular Clones
The cell density was adjusted to 2 × 103/ml, and the cell
suspension was 100 µl per well in the 6-well plates per 2ml of
DMEM supplemented with 10% FBS and 100 U/ml penicillin and
100µg/ml streptomycin. Single-cell-derived clones were grown
for 10 days. The culture was pre-cooled three times with PBS,
the methanol was fixed for 15min, the crystal violet dye was
applied for 20min, and the water was rinsed and air dried.
The number of visible clones was visually counted and a clone
formation rate was calculated: clone formation rate (%)= (clone
number/number of inoculated cells)× 100%. This procedure was
replicated three times.
Endothelial Tube Formation Assay
The sarcoma cell culture medium was changed to serum-
free DMEM medium for 48 h. Then, cell culture media were
collected, centrifuged, and filtered to obtain tumor-conditioned
medium (TCM). Matrigel (50 µl; Corning) was added to
each well of a 96-well plate and allowed to solidify at 37◦C
for 30min. 2 × 104 HUVECs were seeded on the gel with
200 µl of concentrated by ultrafiltration TCM. Then, 5 nM
and 10 nM Tanespimycin and equivalent PBS were added and
incubated at 37◦C. After 8 h, tube formation was observed
under a microscope. The tube-like network was visualized by
a microscope and photographed. The total tube length and the
number of tube branch points were measured using Image-
ProPlus 6.0 Software (MediaCybernetics, USA).
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FIGURE 5 | MRS potential drug discovery. (A) No overlap between DL and LMS was observed in the L1000FWD database. (B) No overlap between DL and LMS was
observed in the DGIdb database. (C) No overlap of DL, LMS, UPS, and MFS was observed in CMap database. (D) DL did not obtain drugs common to L1000FWD,
DGIdb, and CMap. (E) LMS did not obtain drugs common to L1000FWD, DGIdb, and CMap, but they appeared in L1000FWD and CMap. (F) CHEMBL325424 and
SERPINE1 in DL pathological subtype are inhibitory relationship. (G) In the LMS pathological subtype, IEINOTECAN inhibited ISG15; COMPOUND 8H,
CHEMBL24828, and COMPOUND 66 had inhibitory relationships with EPHA7; the relationship between BLEOMYCIN and LIG1 is unknown.
Statistical Analysis
All data were analyzed using the SPSS 21.0 statistical software
program (IBM Corporation, Armonk, NY, USA). Graphs
were generated with GraphPad Prism 8.0 Software (GraphPad
Software, Inc., San Diego, CA). Results are presented as the mean
± standard deviation (SD). Student’s t-tests, chi-squared tests, or
one-way ANOVAs were used where appropriate. A two-tailed p
< 0.05 was required for results to be considered as statistically
significant. p < 0.05 was considered as statistically significant
(∗p < 0.05).
RESULTS
Sample Information Statistics
Clinical sample details are provided in Table 1. A total of 536
samples were obtained, including 250 samples of TCGA and 286
samples of GSE21050. From the sarcoma subtypes identified in
the two datasets, the greatest proportions were found to be DL
(57/57), UPS (49/128), and LMS (100/75), while other subtypes
comprised substantially lower proportions. Overall, the survival
of patients with metastases was significantly lower than that
of patients with no detectable metastases (p < 0.001). In all
four pathological subtypes from TCGA cohort, survival time of
patients with metastases was observed to be significantly lower
than that of patients with no metastases (Figures 1A–D). The
same trends were seen for two pathological subtypes LMS and
UPS from GSE21050 cohort, but no significant difference was
observed for DL subtype (Figures 1E–G).
Identification of MRS
The RNA-seq expression profile data of the TCGA dataset
were used to analyze DEGs (Supplementary Tables 1–4) within
the four sarcoma pathological subtypes in metastatic and non-
metastatic samples. Identified DEGs were defined as MRS.
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FIGURE 6 | qRT-PCR results indicated that (A) ISG15, (B) NUP50, (C) PTTG1, (D) SERPINE1, and (E) TSR1 were highly expressed in the sarcoma tissues. (*p <
0.05).
Identified up-regulated DEGs were more abundant than down-
regulated DEGs in the metastatic samples. A similar trend was
observed in the GSE21050 dataset (Table 2). This indicated that
the occurrence of metastasis may be more likely associated
with up-regulation of certain pathways rather than inhibition.
Comparisons of MRS within different pathological subtypes
revealed that there were very few overlapping genes among
them (Figures 2A,B). Such findings may be related to the high
degree of sarcoma heterogeneity and differences and specificities
of metastatic patterns among different pathological subtypes of
sarcoma. Enrichment analysis of MRS’s GO biology process and
KEGG pathway indicated that MRS patterns in DL and LMS
were mainly related to muscle tissue homeostasis (Figures 2C,D;
Supplementary Tables 5, 6), while MRS patterns in UPS and
MFS were related to forebrain development and fatty acid
degradation (Figures 2E,F; Supplementary Tables 7, 8).
Relationship Between MRS and Prognosis
Using TCGA and GSE21050 dataset prognosis information, we
analyzed the relationship between MRS and metastatic prognosis
of three pathological subtypes, DL, LMS, and UPS, and found
8, 26, and 6 genes (Supplementary Table 9), respectively, that
were significantly linked to prognosis. According to HR (hazard
ratio) >1 or <1, these genes are divided into adverse prognostic
factors and favorable prognostic factors. We found that in the
three pathological subtypes described above, these genes aremore
likely to appear as adverse prognostic factors (HR > 1/HR <
1, Figure 3A, DL: 5/3; Figure 3B, LMS: 18/8; Figure 3C, UPS:
5/1). These findings suggest that the high expression level of these
genes has a positive regulatory effect on metastasis and are linked
to poor prognosis.
MRS Genes
Using TCGA and GSE21050 expression data, we analyzed the
expression of MRS as related to prognosis in DL, LMS, and UPS
pathological subtypes. Overall, these genes could be aggregated
into high- and low-expression groups in both datasets, and a
high degree of consistency was present in expression patterns
within both datasets (Figure 4). In the DL pathological subtype,
the SERPINE1 gene, which showed the highest expression levels
in the TCGA dataset (Figure 4A) and was also highly expressed
in the GSE21050 dataset (Figure 4B), and its expression level
significantly increased in the metastatic vs. non-metastatic group
(Supplementary Table 1). In the LMS pathological subtype,
ISG15 and PTTG1 showed the highest expression levels in
the TCGA (Figure 4C) and GSE21050 (Figure 4D) datasets,
and their expression levels in the metastasis group were
significantly higher than that in the non-metastasis group
(Supplementary Table 2). In the UPS pathological subtype,
we found similar expression patterns of TSR1 and NUP50
(Figures 4E,F; Supplementary Table 3). These results indicate
consistency within identified MRS.
Potential Drug Analysis
The L1000 database provides records of the effect of more
than 16,000 types of drugs and small molecular substances
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FIGURE 7 | Immunohistochemical results indicated that (A) ISG15, NUP50, PTTG1, SERPINE1, and TSR1 were highly expressed in the sarcoma tissues. (B) The
Image-ProPlus 6.0 Software was used to analyze the expression of proteins (*p < 0.05). Clinical details of patients are shown in Table 3.
on gene expression patterns within 1,000 tumor cell lines.
We used the L1000FWD tool to conduct reverse drug
screening for our identified DEGs (including up-regulated
and down-regulated genes) in four sarcoma pathological
subtypes in the TCGA dataset. We have identified 26 and
49 small molecules with q-value <0.05 for DL and LMS
subtypes, respectively, while no molecules with significant
effect on the UPS and MFS subtypes were identified.
Comparing the small-molecule substances with the ability
to affect DL and LMS subtypes, no overlapping small-molecule
substances were found (Figure 5A, Supplementary Table 10).
Similarly, no overlap of small molecules was observed
in the DGIdb and CMap databases (Figures 5B,C;
Supplementary Tables 11, 12). These results suggest that
different sarcoma pathological subtypes will respond differently
to drugs, which highlights the importance of drug screening for
different pathological subtypes.
For DL and LMS, we compared the potential for drug overlap
among L1000, DGIdb, and CMap annotations. For the DL
(Figure 5D) subtype, no drugs common for the three databases
were found. For the LMS (Figure 5E) subtype, although no drug
common to the three databases was found, we did find that the
drug Tanespimycin was identified as potentially affecting MRS in
LMS in both the L1000 and CMap databases. Tanespimycin is
a benzoquinone antitumor antibiotic derived from Geldamycin
TABLE 3 | The clinical pathological characteristics of sarcoma.
Age (years)
<50 4
≥50 6
Gender
Male 6
Female 4
TNM stage
I–II 2
III–IV 8
Type of sarcoma
Uterine leiomyosarcomas 6
Liposarcomas 3
Undifferentiated pleomorphic sarcoma 1
(12); it can inhibit heat shock protein 90 (HSP90). Inhibition
of the HSP90 can promote protein degradation, and this line
of therapy is explored for several types of solid tumor or
chronic myelogenous leukemias (13–15). Based on the DGIdb
database, it was found that in the DL subtype, only the SERPINE1
gene interacted with a drug, CHEMBL325424, that exerted an
inhibitory relationship with SERPINE1 (Figure 5F). Moreover,
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FIGURE 8 | Tanespimycin reduced cell proliferation in a concentration-dependent manner. (A) CCK8. (B) Colony formation (*p < 0.05).
prognostic analysis revealed that inhibition of SERPINE1, which
serves as an adverse prognostic factor (Figure 3A, HR > 1)
by CHEMBL325424 may inhibit metastasis in the DL subtype.
For the LMS subtype, we obtained drugs that interacted
with three genes (Figure 5G); IEINOTECAN inhibited ISG15;
COMPOUND 8H, CHEMBL24828, and COMPOUND 66 had
inhibitory relationships with EPHA7; the relationship between
BLEOMYCIN and LIG1 is unknown. ISG15 and LIG1 were
adverse prognostic factors (Figure 3B, HR > 1), and EPHA7 was
favorable (Figure 3B, HR <1), suggesting that drugs affecting
their functions may have a negative effect on the metastasis of
LMS subtypes.
ISG15, NUP50, PTTG1, SERPINE1, and
TSR1 Expressions Are Up-Regulated in
Sarcoma Tissues
To validate whether ISG15, NUP50, PTTG1, SERPINE1,
and TSR1 are differentially expressed in sarcoma tissues,
we experimentally validated their expression in the tissues
of 10 sarcoma patients. The results of qRT-PCR suggested
that ISG15 (Figure 6A), NUP50 (Figure 6B), PTTG1
(Figure 6C), SERPINE1 (Figure 6D), and TSR1 (Figure 6E)
were highly expressed in sarcoma tissues. The results
of immunohistochemistry indicated that SG15, NUP50,
PTTG1, SERPINE1, and TSR1 were highly expressed in
sarcoma tissues (Figure 7A). The Image-ProPlus 6.0 Software
(MediaCybernetics, USA) was used to statistically analyze the
expression of proteins (Figure 7B) (∗p < 0.05).
Tanespimycin Down-Regulates Cell
Proliferation, Migration, Invasion, and
Angiogenic Ability of Sarcoma Cells
Results obtained from both the CCK8 (Figure 8A) and
colony formation (Figure 8B) assays revealed that Tanespimycin
reduced cell proliferation in sarcoma cell lines in a concentration-
dependent manner. Compared with those in the control group,
cell migration was obviously inhibited in HT1080, SW982,
and SK-UT-1 sarcoma cells after treatment of Tanespimycin
in a concentration-dependent manner. Similarly, exposure
of Tanespimycin also led to a progressive loss of the
invasive ability of HT1080, SW982, and SK-UT-1 cells in a
concentration-dependent manner (Figure 9). Tube formation
assay was used to assess the effect of Tanespimycin on
sarcoma development and the length of tubes was decreased
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FIGURE 9 | Tanespimycin inhibited the migration and invasion of HT1080, SW982, and SK-UT-1 cells, and the inhibition increased with the increase of concentration
(*p < 0.05).
by the higher concentration of Tanespimycin (Figure 10).
These data suggest that Tanespimycin is able to reduce the
proliferation, migration, invasion, and angiogenic ability of
sarcoma cells, and with the higher the concentration, the stronger
the effect.
DISCUSSION
Sarcomas represent a rare tumor type, accounting for ∼1% of
all tumors most commonly occurring in connective tissue (16,
17). While surgical resection remains the primary treatment for
resectable tumors (18), the combination of preoperative (preRT)
or postoperative (PORT) radiotherapy and chemotherapy can
also play a role (19). In this study, we analyzed gene expression
data of 536 sarcoma samples from TCGA and GEO (GSE21050)
databases. The survival time of the patients diagnosed with
sarcomas classified as one of the four pathological subtypes DL,
LMS, UPS, and MFS in the metastasis group and the non-
metastasis group was analyzed. The survival of the patients with
metastases was significantly lower than for patients with no
detectable metastases. When comparing the DEGs in metastatic
vs. non-metastatic samples of the four pathological subtypes, a
set of genes related to metastasis development was identified
as MRS. Few MRS were found to be common among the
different pathological subtypes, indicating that differences in
metastasis patterns were present within the different pathological
subtypes. Results obtained from functional annotations of MRS
revealed that MRS in DL and LMS were mainly related to
biological processes of muscle tissue, while MRS in UPS and
MFS were related to forebrain development and fatty acid
degradation. Prognostic analysis of MRS further identified a
group of genes that were significantly associated with prognosis.
These results indicated that the genes in the three pathological
subtypes DL, LMS, and UPS were more likely to be linked with
adverse prognostic factors, suggesting that the high expression
levels of identified genes exerted a positive regulatory effect
on metastasis, thus accounting for their association with poor
prognosis. Public drug databases such as L1000, DGIdb, and
CMap, were then used to identify a set of potential drugs
(small-molecule substances) with potential to affect identified
MRS. Tanespimycin was identified in both L1000 and CMap
databases, suggesting that it might serve as a drug to treat
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FIGURE 10 | With the increase of Tanespimycin concentration, the proliferation of HUVECs decreased (co-culture with TCM) (*p < 0.05).
metastasis of the LMS subtype. To verify these findings,
qRT-PCR, immunohistochemistry, transwell, cell proliferation,
and neovascularization assays were performed. Taken together,
results of these experiments suggest that high expression
levels of ISG15, NUP50, PTTG1, SERPINE1, and TSR1 exert
a positive regulatory effect on metastasis, suggesting poor
prognosis, and that Tanespimycin may effectively treat LMS
sarcoma subtype.
The ISG15 transcription is abnormally expressed in most
human malignancies and exerts both pro- or anti-tumor
functions (20). ISG15 is considered as a tumor biomarker due
to its high level of expression as confined to tumors (21), and
sensitivity to the anti-cancer drug camptothecin (Topotecan)
(22). ISG15, via the c-MET/Fyn/beta-catenin pathway in
esophageal squamous cell carcinoma, shows tumor-promoting
effects (23). Another gene identified in this study was NUP50.
NUP50 can form a protein cluster with XPO1, which is inhibited
by bortezomib, showing inhibiting activity in multiple myeloma
(24). PTTG1 has also been associated with the occurrence of
tumors. Increased expression of the nuclear protein in PTTG1
was observed in malignant adrenal tumors, and PTTG1 can
serve as a biomarker for this tumor type (25). Overexpression
of PTTG1 is an independent prognostic factor for colorectal
cancer patients, and knockout of PTTG1 can inhibit the growth
and metastasis of colorectal cancer (26). Moreover, PTTG1
promotes the invasion of esophageal squamous cell cancer cells
by inducing epithelial–mesenchymal transformation, and PTTG1
is involved in inducing epithelial–mesenchymal transformation
by activating the expression of GLI1 in esophageal squamous cell
carcinoma (27). Results from a number of studies have shown
that SERPINE1 can be used as a prognostic biomarker for gastric
cancer (28–30). Down-regulation of SERPINE1 can inhibit
the growth of glioma in vivo, and up-regulation of mir-1275
activates the p53 signaling pathway by regulating SERPINE1, thus
inhibiting the proliferation, invasion, and migration of glioma
cells (31). Finally, ADAMTS5’s recombinant TSR1 inhibits the
growth of melanoma in mice by anti-angiogenesis mechanism
(32), and ADAMTS5 can also be used as a prognostic biomarker
for prostate cancer (33).
To our knowledge, there is no literature suggesting that
Tanespimycin can be used to treat sarcomas. It has been
reported that Tanespimycin is a classical inhibitor of Hsp90
(34), and Runx2 is transcriptionally regulated by Hsp90 through
the AKT/gsk-3/catenin signaling pathway, leading to apoptosis
of osteosarcoma cells (35). Our current results suggest that
Tanespimycin inhibits the proliferation and metastasis of
sarcomas in vitro.
In summary, here we demonstrate that ISG15, NUP50,
PTTG1, SERPINE1, and TSR1 are highly expressed in sarcoma
tissues and associated with sarcoma metastasis and poor
prognosis. In addition, we present the first evidence indicating
that Tanespimycin inhibits the proliferation and metastasis of
sarcomas. Taken together, these results provide new insights
into the pathogenesis, diagnosis, treatment, and prognosis
of sarcomas and provide new directions for further study
of sarcomas.
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